Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-masked, Multicenter, Active Comparator-controlled Trial to Investigate the Efficacy and Safety of Intravitreal OLN324 in Adult Participants With Neovascular (Wet) Age-related Macular Degeneration (nAMD)

NCT07816315 is registered in ClinicalTrials.gov with Ollin Biosciences, Inc. as lead sponsor.

NCT NCT07816315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07816315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-masked, Multicenter, Active Comparator-controlled Trial to Investigate the Efficacy and Safety of Intravitreal OLN324 in Adult Participants With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Lead sponsor
Ollin Biosciences, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
December 15, 2029
Enrollment
500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

wet age related macular degeneration